Sinopia Biosciences utilizes high-throughput multi-omics data, machine learning, and network analyses through its LEADS® platform to identify novel drug targets and mechanisms in complex disease models. The company addresses the challenge of drug discovery in diseases with unknown etiology by providing deeper insights into pathologies and therapeutics, particularly for high unmet medical needs like Parkinson's disease.
Funding
$2.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Drug discovery for complex diseases is often hindered by unknown etiologies and intricate pathogenesis, making it difficult to identify effective drug targets and mechanisms. Traditional target-based discovery approaches have limitations, while phenotypic screening can be a "black box" approach with limited insight into underlying biological processes.
Solution
Sinopia Biosciences leverages high-throughput multi-omics data, machine learning, and network analyses through its LEADS® platform to address the challenges of drug discovery in complex diseases. By integrating comprehensive biomolecular measurements with advanced computational methods, the company provides deeper insights into disease pathologies and therapeutic mechanisms. The LEADS® platform enables the identification of key signals within complex datasets, facilitating the discovery of novel drug targets and accelerating the development of first-in-class therapeutics. This data-driven approach allows for a more comprehensive understanding of disease biology, leading to improved predictivity and more effective drug development strategies.
Target Audience
Sinopia Biosciences primarily targets pharmaceutical companies and research institutions seeking to accelerate drug discovery for complex diseases with high unmet medical needs.
Features
- LEADS® platform integrates high-throughput screening (HTS), multi-omics data, AI/machine learning, and network analyses.
- Multi-omics data analysis includes metabolomics, genomics, and other biomolecular measurements.
- AI/machine learning algorithms identify key signals and patterns within complex datasets.
- Network analyses provide insights into disease mechanisms and potential drug targets.
- Focus on first-in-class therapeutics for areas with high unmet clinical need.
- Genome-engineered in vitro models and relevant in vivo models are used for validation.